 |
PDBsum entry 1udu
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of human phosphodiesterase 5 complexed with tadalafil(cialis)
|
|
Structure:
|
 |
Cgmp-specific 3',5'-cyclic phosphodiesterase. Chain: a, b. Fragment: catalytic domain. Synonym: phosphodiesterase 5. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
2.83Å
|
R-factor:
|
0.263
|
R-free:
|
0.374
|
|
|
Authors:
|
 |
B.-J.Sung,J.I.Lee,Y.-S.Heo,J.H.Kim,J.Moon,J.M.Yoon,Y.-L.Hyun,E.Kim, S.J.Eum,T.G.Lee,J.M.Cho,S.-Y.Park,J.-O.Lee,Y.H.Jeon,K.Y.Hwang,S.Ro
|
Key ref:
|
 |
B.J.Sung
et al.
(2003).
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
Nature,
425,
98.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
06-May-03
|
Release date:
|
11-May-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
O76074
(PDE5A_HUMAN) -
cGMP-specific 3',5'-cyclic phosphodiesterase from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
875 a.a.
313 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.1.4.35
- 3',5'-cyclic-GMP phosphodiesterase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
3',5'-cyclic GMP + H2O = GMP + H+
|
 |
 |
 |
 |
 |
3',5'-cyclic GMP
|
+
|
H2O
|
=
|
GMP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Nature
425:98
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
|
|
B.J.Sung,
K.Y.Hwang,
Y.H.Jeon,
J.I.Lee,
Y.S.Heo,
J.H.Kim,
J.Moon,
J.M.Yoon,
Y.L.Hyun,
E.Kim,
S.J.Eum,
S.Y.Park,
J.O.Lee,
T.G.Lee,
S.Ro,
J.M.Cho.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the
intracellular second messengers cyclic AMP and cyclic GMP. As essential
regulators of cyclic nucleotide signalling with diverse physiological functions,
PDEs are drug targets for the treatment of various diseases, including heart
failure, depression, asthma, inflammation and erectile dysfunction. Of the 12
PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolysing
activity in human corpus cavernosum tissue. It is well known as the target of
sildenafil citrate (Viagra) and other similar drugs for the treatment of
erectile dysfunction. Despite the pressing need to develop selective PDE
inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are
currently available. Here we present the three-dimensional structures of the
catalytic domain (residues 537-860) of human PDE5 complexed with the three drug
molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). These
structures will provide opportunities to design potent and selective PDE
inhibitors with improved pharmacological profiles.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2: Stereo view of the active site of the PDE5 -sildenafil
complex. Sildenafil is shown as a stick model with carbon
atoms coloured yellow. Metal- and inhibitor-binding residues of
PDE5 are shown as stick models with carbon atoms coloured white.
The zinc (the bigger CPK model) and magnesium ions are shown in
orange and green, respectively. The amide moiety of the
pyrazolopyrimidinone group of sildenafil forms a bidentate
hydrogen bond with the -amide
group of Gln 817, which is well ordered by a hydrogen bond relay
involving Gln 817 to Gln 775, Gln 775 to Ala 767 and Gln 775 to
Trp 853. The model orientation is the same as in Fig. 1a.
|
 |
Figure 3.
Figure 3: Comparison of PDE5 and PDE4 active sites. a,
Superimposed C traces
of PDE5 (red) and PDE4 (blue)9 showing the difference between
the two folds at the active site. Residues 304 -325 of PDE5 and
660 -680 of PDE4D are shown with deeper colours to emphasize the
differences in this region. The stick model of sildenafil is
shown in yellow and that of zardaverine^9 in green. b, Surface
representation of active site pocket of PDE5. The molecular
surface is coloured according to electrostatic potential
(negative and positive in red and blue, respectively). Residues
that form the active site pocket are shown in green. The bound
sildenafil in PDE5 is shown as a stick model.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nature
(2003,
425,
98-0)
copyright 2003.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Russwurm,
C.Schlicker,
M.Weyand,
D.Koesling,
and
C.Steegborn
(2011).
Crystal structure of the GAF-B domain from human phosphodiesterase 5.
|
| |
Proteins,
79,
1682-1687.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Roegler,
and
J.Lehmann
(2010).
[Medicinal chemistry of nitrates and PDE5 inhibitors].
|
| |
Pharm Unserer Zeit,
39,
351-358.
|
 |
|
|
|
|
 |
R.Raijmakers,
P.Dadvar,
S.Pelletier,
J.Gouw,
K.Rumpel,
and
A.J.Heck
(2010).
Target profiling of a small library of phosphodiesterase 5 (PDE5) inhibitors using chemical proteomics.
|
| |
ChemMedChem,
5,
1927-1936.
|
 |
|
|
|
|
 |
A.Bhattacharya,
A.Biswas,
and
P.K.Das
(2009).
Role of a differentially expressed cAMP phosphodiesterase in regulating the induction of resistance against oxidative damage in Leishmania donovani.
|
| |
Free Radic Biol Med,
47,
1494-1506.
|
 |
|
|
|
|
 |
B.Barren,
L.Gakhar,
H.Muradov,
K.K.Boyd,
S.Ramaswamy,
and
N.O.Artemyev
(2009).
Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.
|
| |
EMBO J,
28,
3613-3622.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.Chang,
T.Grau,
S.Dangel,
R.Hurd,
B.Jurklies,
E.C.Sener,
S.Andreasson,
H.Dollfus,
B.Baumann,
S.Bolz,
N.Artemyev,
S.Kohl,
J.Heckenlively,
and
B.Wissinger
(2009).
A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene.
|
| |
Proc Natl Acad Sci U S A,
106,
19581-19586.
|
 |
|
|
|
|
 |
C.Y.Chen,
Y.H.Chang,
D.T.Bau,
H.J.Huang,
F.J.Tsai,
C.H.Tsai,
and
C.Y.Chen
(2009).
Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis.
|
| |
Acta Pharmacol Sin,
30,
1186-1194.
|
 |
|
|
|
|
 |
H.A.Toque,
F.B.Priviero,
S.M.Zemse,
E.Antunes,
C.E.Teixeira,
and
R.C.Webb
(2009).
Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
|
| |
Clin Exp Pharmacol Physiol,
36,
358-366.
|
 |
|
|
|
|
 |
H.N.Tinsley,
B.D.Gary,
A.B.Keeton,
W.Zhang,
A.H.Abadi,
R.C.Reynolds,
and
G.A.Piazza
(2009).
Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G.
|
| |
Mol Cancer Ther,
8,
3331-3340.
|
 |
|
|
|
|
 |
J.L.Weeks,
J.D.Corbin,
and
S.H.Francis
(2009).
Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.
|
| |
J Pharmacol Exp Ther,
331,
133-141.
|
 |
|
|
|
|
 |
J.Pandit,
M.D.Forman,
K.F.Fennell,
K.S.Dillman,
and
F.S.Menniti
(2009).
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct.
|
| |
Proc Natl Acad Sci U S A,
106,
18225-18230.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Sakamoto,
M.McCluskey,
T.G.Wensel,
J.K.Naggert,
and
P.M.Nishina
(2009).
New mouse models for recessive retinitis pigmentosa caused by mutations in the Pde6a gene.
|
| |
Hum Mol Genet,
18,
178-192.
|
 |
|
|
|
|
 |
P.Dadvar,
D.Kovanich,
G.E.Folkers,
K.Rumpel,
R.Raijmakers,
and
A.J.Heck
(2009).
Phosphatidylethanolamine-binding proteins, including RKIP, exhibit affinity for phosphodiesterase-5 inhibitors.
|
| |
Chembiochem,
10,
2654-2662.
|
 |
|
|
|
|
 |
S.Ahn,
J.Y.Hong,
M.K.Hong,
Y.P.Jang,
M.S.Oh,
J.H.Jung,
and
J.Hong
(2009).
Structural determination of sildenafil and its analogues in dietary supplements by fast-atom bombardment collision-induced dissociation tandem mass spectrometry.
|
| |
Rapid Commun Mass Spectrom,
23,
3158-3166.
|
 |
|
|
|
|
 |
C.C.Heikaus,
J.R.Stout,
M.R.Sekharan,
C.M.Eakin,
P.Rajagopal,
P.S.Brzovic,
J.A.Beavo,
and
R.E.Klevit
(2008).
Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change.
|
| |
J Biol Chem,
283,
22749-22759.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.M.Halpin
(2008).
ABCD of the phosphodiesterase family: interaction and differential activity in COPD.
|
| |
Int J Chron Obstruct Pulmon Dis,
3,
543-561.
|
 |
|
|
|
|
 |
G.Chen,
H.Wang,
H.Robinson,
J.Cai,
Y.Wan,
and
H.Ke
(2008).
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
|
| |
Biochem Pharmacol,
75,
1717-1728.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Wang,
M.Ye,
H.Robinson,
S.H.Francis,
and
H.Ke
(2008).
Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.
|
| |
Mol Pharmacol,
73,
104-110.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Totrov
(2008).
Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR.
|
| |
Chem Biol Drug Des,
71,
15-27.
|
 |
|
|
|
|
 |
S.E.Martinez,
C.C.Heikaus,
R.E.Klevit,
and
J.A.Beavo
(2008).
The structure of the GAF A domain from phosphodiesterase 6C reveals determinants of cGMP binding, a conserved binding surface, and a large cGMP-dependent conformational change.
|
| |
J Biol Chem,
283,
25913-25919.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Liu,
M.N.Mansour,
K.S.Dillman,
J.R.Perez,
D.E.Danley,
P.A.Aeed,
S.P.Simons,
P.K.Lemotte,
and
F.S.Menniti
(2008).
Structural basis for the catalytic mechanism of human phosphodiesterase 9.
|
| |
Proc Natl Acad Sci U S A,
105,
13309-13314.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Xiong,
H.T.Lu,
and
C.G.Zhan
(2008).
Dynamic structures of phosphodiesterase-5 active site by combined molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.
|
| |
J Comput Chem,
29,
1259-1267.
|
 |
|
|
|
|
 |
H.Wang,
Y.Liu,
J.Hou,
M.Zheng,
H.Robinson,
and
H.Ke
(2007).
Structural insight into substrate specificity of phosphodiesterase 10.
|
| |
Proc Natl Acad Sci U S A,
104,
5782-5787.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Conti,
and
J.Beavo
(2007).
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.
|
| |
Annu Rev Biochem,
76,
481-511.
|
 |
|
|
|
|
 |
G.Cirino,
F.Fusco,
C.Imbimbo,
and
V.Mirone
(2006).
Pharmacology of erectile dysfunction in man.
|
| |
Pharmacol Ther,
111,
400-423.
|
 |
|
|
|
|
 |
H.Wang,
Y.Liu,
Q.Huai,
J.Cai,
R.Zoraghi,
S.H.Francis,
J.D.Corbin,
H.Robinson,
Z.Xin,
G.Lin,
and
H.Ke
(2006).
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
|
| |
J Biol Chem,
281,
21469-21479.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Corbin,
S.Francis,
and
R.Zoraghi
(2006).
Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil.
|
| |
Int J Impot Res,
18,
251-257.
|
 |
|
|
|
|
 |
Q.Huai,
Y.Sun,
H.Wang,
D.Macdonald,
R.Aspiotis,
H.Robinson,
Z.Huang,
and
H.Ke
(2006).
Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.
|
| |
J Med Chem,
49,
1867-1873.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Zoraghi,
J.D.Corbin,
and
S.H.Francis
(2006).
Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
|
| |
J Biol Chem,
281,
5553-5558.
|
 |
|
|
|
|
 |
Y.Xiong,
H.T.Lu,
Y.Li,
G.F.Yang,
and
C.G.Zhan
(2006).
Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.
|
| |
Biophys J,
91,
1858-1867.
|
 |
|
|
|
|
 |
C.C.Carson,
and
T.F.Lue
(2005).
Phosphodiesterase type 5 inhibitors for erectile dysfunction.
|
| |
BJU Int,
96,
257-280.
|
 |
|
|
|
|
 |
D.Shin,
Y.S.Heo,
K.J.Lee,
C.M.Kim,
J.M.Yoon,
J.I.Lee,
Y.L.Hyun,
Y.H.Jeon,
T.G.Lee,
J.M.Cho,
and
S.Ro
(2005).
Structural chemoproteomics and drug discovery.
|
| |
Biopolymers,
80,
258-263.
|
 |
|
|
|
|
 |
E.Carosa,
F.Lombardo,
P.Martini,
F.Brandetti,
and
E.A.Jannini
(2005).
The therapeutic dilemma: how to use tadalafil.
|
| |
Int J Androl,
28,
74-80.
|
 |
|
|
|
|
 |
H.Wang,
Y.Liu,
Y.Chen,
H.Robinson,
and
H.Ke
(2005).
Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
|
| |
J Biol Chem,
280,
30949-30955.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.I.Castro,
C.Hermsen,
J.E.Schultz,
and
J.U.Linder
(2005).
Adenylyl cyclase Rv0386 from Mycobacterium tuberculosis H37Rv uses a novel mode for substrate selection.
|
| |
FEBS J,
272,
3085-3092.
|
 |
|
|
|
|
 |
R.Zoraghi,
E.P.Bessay,
J.D.Corbin,
and
S.H.Francis
(2005).
Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation.
|
| |
J Biol Chem,
280,
12051-12063.
|
 |
|
|
|
|
 |
X.Zhang,
Q.Feng,
and
R.H.Cote
(2005).
Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors.
|
| |
Invest Ophthalmol Vis Sci,
46,
3060-3066.
|
 |
|
|
|
|
 |
A.McCullough
(2004).
Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
|
| |
Curr Urol Rep,
5,
451-459.
|
 |
|
|
|
|
 |
E.Carosa,
P.Martini,
F.Brandetti,
S.M.Di Stasi,
F.Lombardo,
A.Lenzi,
and
E.A.Jannini
(2004).
Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels.
|
| |
Clin Endocrinol (Oxf),
61,
382-386.
|
 |
|
|
|
|
 |
G.L.Card,
B.P.England,
Y.Suzuki,
D.Fong,
B.Powell,
B.Lee,
C.Luu,
M.Tabrizizad,
S.Gillette,
P.N.Ibrahim,
D.R.Artis,
G.Bollag,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
K.Y.Zhang
(2004).
Structural basis for the activity of drugs that inhibit phosphodiesterases.
|
| |
Structure,
12,
2233-2247.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.M.O'Donnell,
and
H.T.Zhang
(2004).
Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).
|
| |
Trends Pharmacol Sci,
25,
158-163.
|
 |
|
|
|
|
 |
K.E.Broderick,
L.Kean,
J.A.Dow,
N.J.Pyne,
and
S.A.Davies
(2004).
Ectopic expression of bovine type 5 phosphodiesterase confers a renal phenotype in Drosophila.
|
| |
J Biol Chem,
279,
8159-8168.
|
 |
|
|
|
|
 |
K.Y.Zhang,
G.L.Card,
Y.Suzuki,
D.R.Artis,
D.Fong,
S.Gillette,
D.Hsieh,
J.Neiman,
B.L.West,
C.Zhang,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
G.Bollag
(2004).
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.
|
| |
Mol Cell,
15,
279-286.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Q.Huai,
H.Wang,
W.Zhang,
R.W.Colman,
H.Robinson,
and
H.Ke
(2004).
Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding.
|
| |
Proc Natl Acad Sci U S A,
101,
9624-9629.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Q.Huai,
Y.Liu,
S.H.Francis,
J.D.Corbin,
and
H.Ke
(2004).
Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.
|
| |
J Biol Chem,
279,
13095-13101.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Kunz,
T.Kloeckner,
L.O.Essen,
T.Seebeck,
and
M.Boshart
(2004).
TbPDE1, a novel class I phosphodiesterase of Trypanosoma brucei.
|
| |
Eur J Biochem,
271,
637-647.
|
 |
|
|
|
|
 |
T.Yoshimura,
I.Sagami,
Y.Sasakura,
and
T.Shimizu
(2003).
Relationships between heme incorporation, tetramer formation, and catalysis of a heme-regulated phosphodiesterase from Escherichia coli: a study of deletion and site-directed mutants.
|
| |
J Biol Chem,
278,
53105-53111.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |